The Difference Between BLA and Non-BLA Skin Substitutes

JARALL Medical Management•February 26, 2026Webinar

In this edition of The JARALL Quarterly, we explore the critical differences between BLA (Biologics License Application) and non-BLA skin substitutes — and why it matters for your podiatry practice's wound care billing.

What You'll Learn

•

BLA vs. Non-BLA Classification: how the FDA categorizes skin substitutes and cellular tissue-based products (CTPs)

•

Billing and Reimbursement Impact: how product classification affects Medicare coverage and reimbursement rates

•

LCD Updates for 2026: the latest Local Coverage Determination changes and which products are covered, under MAC discretion, or non-covered

•

Product Selection Strategy: practical guidance on choosing the right products for your practice

Why This Matters

With the updated LCDs effective January 1, 2026, understanding the distinction between BLA and non-BLA products is more important than ever. Product classification directly impacts whether Medicare will reimburse for a given skin substitute — and choosing the wrong product can mean denied claims and lost revenue.

Watch the full webinar above for a detailed walkthrough of the current landscape and actionable steps for your practice.

Meet Aurora

The JARALL Reporting Platform (JRP) has a new name, a new identity, and powerful new capabilities. Effective immediately, the JRP is now Aurora.

July 9, 2026

The Podiatrist's Guide to Mastering Modifiers: Protecting Revenue and Compliance

Modifiers are the two-character codes that tell a payer what actually happened during a visit. Get them wrong and the claim denies. Here is how to apply Modifier 25, the RT, LT, and digital modifiers, Modifier 59 and its X subsets, and the Q7, Q8, and Q9 routine foot care anchors.

July 2, 2026

Anatomy of a Clean Claim: From Front Desk to Full Reimbursement

A 'clean claim' — one that sails through the clearinghouse and pays on the first pass, with no manual intervention and no rejection flags — is the difference between healthy cash flow and a revenue cycle that stalls. We trace a claim through its four phases, from front-desk eligibility checks and point-of-care documentation to podiatric coding precision and clearinghouse scrubbing, and show why a 95%+ first-pass rate is a discipline, not luck.